Payment overview · 2025
General Payments
$17.24
1 reported records · 1 companies
Healthcare provider profile · identity verified
Andrew M Romanowsky, MD
Allopathic & Osteopathic Physicians|Internal Medicine · LOWELL, MA · NPI 1578883237
Verified facts
What the public records show
CMS Open Payments records show Andrew M Romanowsky, MD received $17.24 in general payments during 2025 across 1 reported records.
GlaxoSmithKline, LLC. accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 115 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.24 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $17.24 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $17.24 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 115 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
115 | 27 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 999 | 256 |
| Lisinopril | Lisinopril | 967 | 260 |
| Amlodipine Besylate | Amlodipine Besylate | 728 | 191 |
| Omeprazole | Omeprazole | 559 | 146 |
| Simvastatin | Simvastatin | 525 | 146 |
| Losartan Potassium | Losartan Potassium | 497 | 131 |
| Levothyroxine Sodium | Levothyroxine Sodium | 474 | 122 |
| Pravastatin Sodium | Pravastatin Sodium | 471 | 127 |
| Alprazolam | Alprazolam | 462 | 86 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 369 | 102 |
| Metoprolol Succinate | Metoprolol Succinate | 338 | 98 |
| Metformin Hcl | Metformin Hcl | 326 | 86 |
| Sertraline Hcl | Sertraline Hcl | 312 | 82 |
| Lorazepam | Lorazepam | 310 | 64 |
| Gabapentin | Gabapentin | 305 | 61 |
| Hydrochlorothiazide | Hydrochlorothiazide | 304 | 86 |
| Eliquis | Apixaban | 292 | 67 |
| Furosemide | Furosemide | 283 | 75 |
| Atenolol | Atenolol | 281 | 77 |
| Allopurinol | Allopurinol | 236 | 56 |
| Oxycodone Hcl | Oxycodone Hcl | 232 | 42 |
| Tamsulosin Hcl | Tamsulosin Hcl | 223 | 51 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 214 | 69 |
| Pantoprazole Sodium | Pantoprazole Sodium | 197 | 53 |
| Ozempic | Semaglutide | 186 | 39 |
| Trazodone Hcl | Trazodone Hcl | 162 | 49 |
| Tramadol Hcl | Tramadol Hcl | 159 | 40 |
| Glipizide Er | Glipizide | 153 | 43 |
| Clopidogrel | Clopidogrel Bisulfate | 143 | 38 |
| Metoprolol Tartrate | Metoprolol Tartrate | 124 | 42 |
| Metformin Hcl Er | Metformin Hcl | 122 | 28 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 115 | 27 |
| Ezetimibe | Ezetimibe | 112 | 32 |
| Zolpidem Tartrate | Zolpidem Tartrate | 107 | 23 |
| Labetalol Hcl | Labetalol Hcl | 98 | 23 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 97 | 21 |
| Alendronate Sodium | Alendronate Sodium | 94 | 28 |
| Carvedilol | Carvedilol | 92 | 19 |
| Irbesartan | Irbesartan | 91 | 23 |
| Celecoxib | Celecoxib | 89 | 22 |
| Clonidine Hcl | Clonidine Hcl | 86 | 18 |
| Torsemide | Torsemide | 86 | 19 |
| Xarelto | Rivaroxaban | 85 | 18 |
| Glipizide | Glipizide | 83 | 17 |
| Finasteride | Finasteride | 75 | 20 |
| Spironolactone | Spironolactone | 75 | 21 |
| Prednisone | Prednisone | 74 | 53 |
| Fluoxetine Hcl | Fluoxetine Hcl | 73 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 72 | 33 |
| Jardiance | Empagliflozin | 72 | 19 |
| Potassium Chloride | Potassium Chloride | 72 | 21 |
| Hydralazine Hcl | Hydralazine Hcl | 71 | 18 |
| Famotidine | Famotidine | 68 | 19 |
| Montelukast Sodium | Montelukast Sodium | 68 | 14 |
| Valsartan | Valsartan | 67 | 22 |
| Clonazepam | Clonazepam | 62 | 13 |
| Chlorthalidone | Chlorthalidone | 61 | 19 |
| Meloxicam | Meloxicam | 61 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 60 | 21 |
| Synthroid | Levothyroxine Sodium | 59 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 57 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 57 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 56 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 56 | 13 |
| Ibuprofen | Ibuprofen | 55 | 15 |
| Mounjaro | Tirzepatide | 55 | 14 |
| Incruse Ellipta | Umeclidinium Bromide | 52 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 52 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 52 | 25 |
| Trulicity | Dulaglutide | 51 | 16 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 49 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 48 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 47 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 47 | 13 |
| Januvia | Sitagliptin Phosphate | 46 | suppressed |
| Lovastatin | Lovastatin | 45 | 13 |
| Warfarin Sodium | Warfarin Sodium | 43 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 42 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 42 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 42 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 40 | 11 |
| Amiodarone Hcl | Amiodarone Hcl | 39 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 39 | 38 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 39 | 11 |
| Dilt-Xr | Diltiazem Hcl | 38 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 38 | 11 |
| Farxiga | Dapagliflozin Propanediol | 37 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 37 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 34 | suppressed |
| Mirtazapine | Mirtazapine | 33 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | 12 |
| Meclizine Hcl | Meclizine Hcl | 32 | 22 |
| Paroxetine Hcl | Paroxetine Hcl | 32 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 32 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 31 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 30 | suppressed |
| Azithromycin | Azithromycin | 29 | 27 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 29 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 28 | 18 |
| Fentanyl | Fentanyl | 27 | suppressed |
| Naproxen | Naproxen | 27 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 26 | 22 |
| Entresto | Sacubitril/Valsartan | 26 | suppressed |
| Folic Acid | Folic Acid | 26 | suppressed |
| Nifedipine Er | Nifedipine | 26 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 25 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 25 | suppressed |
| Ursodiol | Ursodiol | 25 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 24 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 24 | 21 |
| Bupropion Xl | Bupropion Hcl | 23 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Risperidone | Risperidone | 23 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 22 | suppressed |
| Glimepiride | Glimepiride | 22 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Amoxicillin | Amoxicillin | 21 | 15 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Pregabalin | Pregabalin | 21 | suppressed |
| Indomethacin | Indomethacin | 20 | suppressed |
| Jantoven | Warfarin Sodium | 20 | suppressed |
| Olanzapine | Olanzapine | 20 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 19 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 19 | suppressed |
| Eplerenone | Eplerenone | 19 | suppressed |
| Lidocaine | Lidocaine | 19 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 19 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 19 | suppressed |
| Repatha Syringe | Evolocumab | 19 | suppressed |
| Topiramate | Topiramate | 19 | suppressed |
| Diazepam | Diazepam | 18 | suppressed |
| Digoxin | Digoxin | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 17 |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 17 | 17 |
| Bupropion Hcl | Bupropion Hcl | 16 | suppressed |
| Colchicine | Colchicine | 16 | 11 |
| Hydrocortisone | Hydrocortisone | 16 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 16 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 16 | suppressed |
| Aripiprazole | Aripiprazole | 15 | suppressed |
| Gemfibrozil | Gemfibrozil | 15 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 15 | suppressed |
| Methadone Hcl | Methadone Hcl | 15 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | 12 |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Oxycontin | Oxycodone Hcl | 15 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 15 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 14 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Cephalexin | Cephalexin | 13 | suppressed |
| Fluticasone-Salmeterol Hfa | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 13 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Anastrozole | Anastrozole | 12 | suppressed |
| Azathioprine | Azathioprine | 12 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 12 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Nystop | Nystatin | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Ativan | Lorazepam | 11 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 11 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 11 | suppressed |
| Phenytoin | Phenytoin | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $17.24 · 1 records | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error